Chemomab Therapeutics Ltd. has announced the presentation of positive Phase 2 clinical data for their investigational drug, nebokitug, at BSG Live'25, the annual scientific meeting of the British Society for Gastroenterology in Glasgow, UK. The data, from the SPRING trial, indicates that nebokitug is well-tolerated and associated with significant improvements in fibrotic and inflammatory biomarkers in patients with primary sclerosing cholangitis $(PSC.AU)$. These improvements suggest a potential slowing of disease progression. The findings support the advancement of nebokitug to a Phase 3 trial, positioning it as a potential first-in-class treatment for PSC. The results were presented by Professor Douglas Thorburn, the Principal Investigator of the SPRING trial.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。